RSH.AX Respiri Limited ASX at A$0.033 intraday bounce: monitor volume

The RSH.AX stock is trading at A$0.033 in intraday trade on 19 Feb 2026 as a short-term oversold bounce unfolds on the ASX. Volume is 579,396.00 shares versus an average of 870,341.00, and the share price sits well below its 50-day average of A$0.04058. The move creates a low-risk setup for nimble traders if volume confirms a rebound. We outline technical triggers, valuation signals and a clear trade plan for Australia-listed Respiri Limited (ASX: RSH.AX) in the sections below.

Intraday setup for RSH.AX stock

Price opened at A$0.030 and is now A$0.033 with a day low of A$0.030 and a day high of A$0.033. The intraday bounce follows a steep YTD slide of -58.23%, signalling an oversold condition and a potential mean-reversion trade for short-term buyers.

Volume of 579,396.00 shares is 0.67x the average, so the rebound currently lacks decisive participation. Watch for a rise above A$0.040 on expanding volume for a higher-probability follow-through.

Technical triggers and oversold bounce signals

The stock is below its 50-day average A$0.04058 and 200-day average A$0.05309, classic technical conditions for an oversold bounce. Short-term traders should look for a close above A$0.036 and a next target at A$0.050 to confirm strength.

Relative volume and daily range expansion are the key confirmations. If RSI and MACD readouts pick up with higher volume, the intraday bounce can turn into a multi-session rally.

Fundamentals, valuation and key metrics

Respiri Limited is an Australian healthcare SaaS and medical device company with a market cap of A$51,984,240.00 and 1,575,280,000 shares outstanding. Trailing EPS is -0.01 and PE is -3.30, reflecting negative earnings. Price-to-sales is elevated at 113.77 and price-to-book sits at 12.74, highlighting valuation risk relative to the healthcare sector average P/B of 4.02.

The balance sheet shows a current ratio of 1.18 and debt-to-equity of 0.49. These metrics support continued operations, but thin revenue and negative cash flow require monitoring of quarterly updates and any capital raises.

Meyka AI grade, model forecast and technical outlook

Meyka AI rates RSH.AX with a score out of 100: 67.50 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

Meyka AI’s forecast model projects a 1-year price of A$0.06970, implying an upside of 111.15% versus the current A$0.033. Forecasts are model-based projections and not guarantees. Traders should weigh the model’s long-run projection against near-term technical confirmation before committing capital.

Price targets, risk limits and a trade plan

Realistic near-term price targets for an oversold bounce are A$0.050 (first target) and A$0.100 (bull case). A tactical stop-loss at A$0.025 limits downside if the stock fails to hold intraday support. position sizing should reflect the high volatility and low liquidity.

For investors, consider a phased approach: small starter position on confirmation above A$0.036, add on a clear close above A$0.050, and reassess fundamentals and earnings progress.

Sector context and catalysts to watch

Respiri operates in Healthcare — Medical Devices — on the ASX in Australia. The sector YTD performance is -5.92%, and larger peers like CSL and ResMed trade with stronger fundamentals and liquidity. Positive catalyst triggers for RSH.AX would include clinical updates, revenue growth beats, or new commercial partnerships.

Watch the company website and ASX announcements. For filings and official notices see the Respiri site and the ASX company page for real-time releases Respiri website and ASX company page.

Final Thoughts

Short-term traders can treat the intraday move in RSH.AX stock at A$0.033 as a textbook oversold bounce candidate but only on clear volume confirmation. The company’s fundamentals remain weak: negative EPS (-0.01), a negative PE (-3.30) and high price-to-sales (113.77) heighten risk for longer-term holders. Meyka AI rates RSH.AX 67.50/100 (Grade B, HOLD) and its forecast model projects A$0.06970 in 12 months, implying 111.15% upside from today’s price; forecasts are model-based projections and not guarantees. Traders should use tight risk controls: a pass if volume stays muted, a starter position above A$0.036, and an exit plan near A$0.025 stop-loss or at the targets A$0.050 and A$0.100. Remember this is a high-volatility, low-liquidity ASX small cap in AUD, so size positions accordingly and monitor company updates closely via ASX filings and official releases.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.